Viewing nowCombinationJanuaRin Duo Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
IlYang Pharmaceutical Co., Ltd.

MFDS item code 202200306 · Approved 2022.01.19 · Insurance code 641706200
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar along with diet and exercise in patients with type 2 diabetes. It may be prescribed when previous diabetes medication treatment has not been received or when blood sugar control is difficult with monotherapy. It is also used when metformin or sitagliptin alone is insufficient or as a substitute for a treatment involving both medications. In cases where blood sugar control is difficult with a combination therapy of metformin and sulfonylureas, or metformin and thiazolidinediones, this medication is added for combination treatment. If dual therapy with insulin and metformin is insufficient, it can also be used to improve blood sugar control. It effectively assists in blood sugar control through various stages of treatment.
For antidiabetic therapy, determine the dose of this medicine based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this medicine should not be initiated because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).
This medication contains sitagliptin and metformin and is used for the treatment of type 2 diabetes. First of all, allergic reactions such as rash may occur while taking this medication; if any allergic symptoms or skin rash appear, stop taking it immediately and consult your physician. This medication may induce acute pancreatitis, so if you experience abdominal pain, nausea, or vomiting following its use, inform your medical staff immediately. In addition, metformin ingredients can cause a serious metabolic disturbance known as lactic acidosis, so patients with impaired renal function or liver dysfunction should not use this medication and should undergo regular kidney function tests. This medication carries a risk of hypoglycemia; caution is advised in case of irregular meals, intense exercise, or concomitant use with other hypoglycemic agents. Particularly, it should not be administered to patients with reduced kidney function, dehydration, severe infections, heart failure, or unstable conditions such as acute myocardial infarction. Administration of this medication should be temporarily suspended before and after tests using iodinated contrast agents, and then resumed only after confirming normal kidney function. Pregnant or breastfeeding women and children and adolescents under 18 should avoid taking this medication. Elderly patients may have reduced kidney function, so dosage adjustment and regular monitoring of kidney function are necessary. It is recommended to avoid alcohol consumption while taking this medication and to stop temporarily before and after surgery. Additionally, this medication may interact with other drugs, so if you are taking other medications, be sure to inform your healthcare provider. During treatment, side effects such as diarrhea, nausea, headache, and upper respiratory infections may occur, and if symptoms are severe, consult your healthcare provider. Finally, if an overdose occurs, visit the hospital immediately for appropriate treatment, as this medication can be partially removed via hemodialysis.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering, ideally at a temperature between 1 and 30 degrees Celsius.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
IlYang Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.